[ad_1]
Virologists point out that there are several Chinese vaccines, the low efficacy vaccine is Sinovac, but there are also other products, such as BBIBP-CorV, developed by Sinopharm.
This vaccine is a whole killed virus preparation that contains one of the most widely used vaccine adjuvants, aluminum hydroxide. Adjuvants help the body to direct attention to the dead virus ingested. In terms of doses, they are two doses administered 21 days apart. In terms of technology, it is one of the first generation vaccines, so it requires more complex manufacturing processes (which is not related to quality).
The first and second phase trials of the BBIBP-CorV vaccine were conducted in people aged 18 to 60 and 60 to 79 years, a total of 644 people were studied, of which 480 received the vaccine formulation. No serious adverse reactions occurred in the experiments, with moderate adverse reactions (fever, nausea) in 4% of subjects. Virologists note that between 8% and 17% of the participants experienced fever after receiving the Pfizer vaccine.
Virologists add that the actual efficacy and any rare side effects that may occur will be read from the data from the triple clinical phase (tests in the order of tens of thousands in humans). All you know is that the indicative data for the countries where it is used shows an overall efficiency of 79.35%.
Pécs virologists find that BBIBP-CorV, when tested in hundreds, is safe (without serious side effects) and well tolerated at all doses tested, and induces an adequate immune response. It contains the most commonly used adjuvant for its components, aluminum hydroxide.
In general, the Pécs virologists believe that if the favorable profile is maintained in the triple test phase and is approved and approved by the European Union and the Hungarian authorities, they would administer the Chinese vaccine.
Cover image: Getty Images
[ad_2]
